OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
915
Results
Show all
Save search
Copy query
Show results for
Unknown
(881)
Clinical
(10)
Proteomics
(10)
Genomics
(7)
Transcriptomics
(6)
Other
(1)
Organisms
Homo sapiens
(8)
Paracentrotus lividus
(7)
Amphibalanus amphitrite
(7)
Acanthamoeba polyphaga mimivirus
(7)
Cyprinus carpio
(7)
Halorubrum lacusprofundi ATCC 49239
(7)
Insecta
(7)
Limosilactobacillus mucosae LM1
(7)
Acanthamoeba polyphaga
(7)
Tepidimicrobium xylanilyticum
(7)
Aiptasia
(7)
Tepidanaerobacter acetatoxydans
(7)
Methanothermobacter thermautotrophicus
(7)
Acetomicrobium mobile
(7)
Acetivibrio thermocellus
(7)
Thermoclostridium stercorarium
(7)
Mycolicibacterium smegmatis
(7)
Coprothermobacter proteolyticus
(7)
Pseudomonas aeruginosa PA14
(7)
Aspergillus niger ATCC 13496
(7)
Salmonella enterica subsp. enterica serovar Cerro
(7)
Streptococcus thermophilus
(7)
Streptomyces sp. MC1
(7)
Hippophae rhamnoides
(7)
Trypanosoma evansi
(7)
Schistosoma japonicum
(7)
Argulus foliaceus
(7)
Oenothera glazioviana
(7)
NEWT:2126719
(7)
Ruditapes decussatus
(7)
Organisms
Homo sapiens
(5)
Cricetulus griseus
(1)
Repository
pride
(7)
ENA
(7)
geo
(5)
biostudies-arrayexpress
(3)
MassIVE
(2)
Tissue
Blood plasma
(1)
Permanent cell line cell
(1)
Disease
Colorectal Neoplasms
(3)
Breast Neoplasms
(1)
Colitis
(1)
Patients with metastatic ColoRectal Cancer (mCRC)
(1)
Malignant neoplasm of colon, unspecified
(1)
First-line treatment of RAS mutated PMMR /MSS advanced colorectal cancer
(1)
Malignant neoplasm of colon
(1)
Colorectal cancer
(1)
Technology Type
Mass Spectrometry
(7)
Top-down proteomics
(2)
Chemical cross-linking coupled with mass spectrometry proteomics
(2)
Olink affinity proteomics
(1)
All-ion fragmentation
(1)
SWATH MS
(1)
Shotgun proteomics
(1)
Instrument Platform
Gene Titan
(1)
Orbitrap Fusion Eclipse
(1)
Q Exactive Plus
(1)
Publication Date
2022
(5)
2026
(2)
2024
(2)
2019
(2)
2015
(1)
2009
(1)
2023
(1)
2020
(1)
2025
(1)
2018
(1)
First Public Date
2024
(3)
2026
(1)
2023
(1)
2020
(1)
2019
(1)
Study status
Completed
(4)
Not yet recruiting
(2)
Not provided
(2)
Active, not recruiting
(1)
Recruiting
(1)
Study type
Interventional
(8)
Transcription profiling by array
(3)
Observational
(2)
Release Date
2022
(126)
2024
(111)
2023
(109)
2021
(102)
2020
(89)
2025
(87)
2018
(65)
2019
(63)
2017
(45)
2016
(36)
2026
(20)
2015
(12)
2014
(8)
2013
(5)
2012
(2)
2011
(2)
2009
(1)
2010
(1)
Lab affiliation
1: Department of Molecular Biology, Division of Chemistry andBioanalytics, University of Salzburg, Hellbrunner Strasse 34, 5020 Salzburg, Austria 2: Christian Doppler Laboratory for Innovative Tools for Biosimilar Characterization, University of Salzburg, Hellbrunner Strasse 34, 5020 Salzburg, Austria
(2)
GlycoAnalytics Group Bioprocessing Technology Institute Agency for Science, Technology, and Research (A*STAR) Singapore
(1)
Cancer Center of Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
(1)
Department of Pharmaceutical Chemistry and Bioanalytics, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Str. 3, Halle/Saale D-01620, Germany Center for Structural Mass Spectrometry, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Str. 3, Halle/Saale D-01620, Germany
(1)
Department of Biomolecular Sciences University of Mississippi
(1)
NBE-DMPK Innovative BioAnalytics, Merck Serono RBM S.p.A., an affiliate of Merck KGaA, Darmstadt, Germany, Via Ribes 1, 10010 Colleretto Giacosa (TO)
(1)
Location
India
(4)
Ukraine
(3)
China
(3)
Argentina
(3)
Brazil
(3)
Russia
(2)
Saudi Arabia
(1)
New Zealand
(1)
Peru
(1)
Spain
(1)
Tags
xref:PubMed:32231428
(1)
xref:PubMed:39488254
(1)
xref:PubMed:38691456
(1)
Keyword
Bevacizumab
(2)
Fluorouracil
(2)
Comparability
(1)
Zirabev
(1)
QL1101
(1)
JS001
(1)
Tripleitriumab
(1)
VEGF
(1)
Antiangiogenic
(1)
PD-1
(1)
Infliximab
(1)
Remsima
(1)
Biosimilar
(1)
Fistulizing Crohn’s Disease
(1)
Observational
(1)
Follow up
(1)
Safety
(1)
Effectiveness
(1)
Disease modifying anti-rheumatic drugs
(1)
Tumor necrosis factor-alpha inhibitors
(1)
First-line treatment
(1)
MCRC
(1)
Folic Acid
(1)
Metastatic
(1)
Metastatic colorectal cancer
(1)
Irinotecan
(1)
Immunotherapy
(1)
Leucovorin
(1)
Levoleucovorin
(1)
Oxaliplatin
(1)
Previous
page
1 / 92
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
92
Next
page
Sort
by:
Relevance
Page size
10
Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.
Not available
S-EPMC8069914
|
biostudies-literature
Cite
MAM Nature Protocol 2022-Investigational chimeric IgG1mAb biosimilar
Peptide mapping experiment on a chimeric IgG1 mAb investigational biosimilar. Three replicates are provided as 1, 2 and 3.
ORGANISM(S):
Igg1 Monoclonal Antibody
2022-03-15
|
MSV000089060
|
MassIVE
Cite
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Not available
S-EPMC8578069
|
biostudies-literature
Cite
The Future of Biosimilar Insulins.
Not available
S-EPMC5001215
|
biostudies-literature
Cite
Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates.
Not available
S-EPMC8033751
|
biostudies-literature
Cite
Introduction of biosimilar insulins in Europe.
Not available
S-EPMC5637898
|
biostudies-literature
Cite
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.
Not available
S-EPMC9485085
|
biostudies-literature
Cite
Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.
Not available
S-EPMC8847209
|
biostudies-literature
Cite
The Path Towards a Tailored Clinical Biosimilar Development.
Not available
S-EPMC7211192
|
biostudies-literature
Cite
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
Not available
S-EPMC11530514
|
biostudies-literature
Cite
Previous
page
1 / 92
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
92
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
